Oncology News Central Peer-Spectives

Post-EHA 2021: Latest Treatment Trends in the Management of Chronic Lymphocytic Leukemia (CLL)

Non-Small Cell Lung Cancer Clinical Highlights From ASCO 2021

Jeffrey Crawford, MD, and Robert Figlin, MD, discuss highlights from ASCO ’21 including immunotherapy, adjuvant and neoadjuvant therapy ie IMpower010 and Checkmate-816, and finish up with a discussion regarding molecular tests, MYLUNG, and NGS as it applies to NSCLC.

Colorectal Cancer Clinical Highlights From ASCO 2021

Andrew Hendifar, MD, and Robert Figlin, MD, discuss highlights from the 2021 ASCO annual meeting, including immunotherapy in MSI-H/dMMR metastatic CRC patients, looking for DEEPER responses in RAS-wild type tumors, the need for testing for HER2+ CRC patients, and liquid biopsy and the CHRONOS trial.

Breast Cancer Clinical Highlights from ASCO 2021

Erika Hamilton, MD, of the Sarah Cannon Research Institute, and Robert Figlin, MD, of Cedars-Sinai Medical Center, discuss breast cancer research from the 2021 annual meeting of the American Society of Clinical Oncology, including adjuvant and neo-adjuvant breast cancer, metastatic disease, the role of CDK 4/6 inhibitors and PARP inhibitors, the potential of SERDs, and a negative study.

Non Small Cell Lung Cancer (NSCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss the different driver mutations in non small cell lung cancer ...

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss the different driver mutations in Non Small Cell Lung Cancer (NSCLC) and how to use them to guide treatment

Small Cell Lung Cancer (SCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss clinical progress in small cell lung cancer (SCLC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss clinical progress in Small Cell Lung Cancer (SCLC)

Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone's Perlmutter Cancer Center, discuss clinical progress in bladder cancer

Prostate Cancer – Robert Figlin, MD, and Neeraj Agarwal, MD, discuss clinical progress in prostate cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Neeraj Agarwal, MD, Professor of Medicine, Huntsman Cancer Institute, Presidential Endowed Chair of Cancer Research , Co-Leader, HCI Experimental Therapeutics Program, Director, Center of Investigational Therapeutics, Director, Genitourinary Oncology Program, Huntsman Cancer Institute, University of Utah, discuss clinical progress in prostate cancer

Renal Cell Carcinoma (RCC) – Robert Figlin, MD and Toni Choueiri, MD, discuss clinical progress in renal cell carcinoma (RCC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Toni Choueiri, MD, Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute, discuss clinical progress in renal cell carcinoma (RCC)

Breast Cancer – Robert Figlin, MD, and Adam Brufsky, MD, PhD, discuss clinical highlights from SABCS 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Adam Brufsky, MD, PhD, Professor of Medicine, Associate Division Chief for the Division of Hematology/Oncology, UPMC, discuss clinical highlights from SABCS 2020